← Back
FDA draft guidance may turn diversity in clinical trials from nice-to-have into a must-have
May 2022 - To make increased diversity a reality, sponsors will need concrete plans to bring new participants into the fold — no easy task.
“It’s already difficult to recruit for clinical trials. It’s already difficult to bring medications to market. We already know all the stats about how many trials failed to recruit, and how many trials are delayed by years just because you can’t find the right patient. So, there is certainly going to be some apprehension,” Gratton says.